Jennifer Pietenpol (Joe Howell for Vanderbilt)
Back to the drawing board for triple-negative breast cancer targets, researchers propose new combo approach
The reason why triple-negative breast cancer is such a tough disease to treat is largely given away in its name. Such tumors can’t be defined by traditional biomarkers — neither estrogen receptors, progesterone receptors, nor excess HER2 protein — forcing drug hunters down uncharted new pathways.
Researchers at Vanderbilt-Ingram Cancer Center explored one of them, and turned up with some new suggestions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
